BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30595535)

  • 21. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
    Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
    PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SPOP mutation induces DNA methylation via stabilizing GLP/G9a.
    Zhang J; Gao K; Xie H; Wang D; Zhang P; Wei T; Yan Y; Pan Y; Ye W; Chen H; Shi Q; Li Y; Zhao SM; Hou X; Weroha SJ; Wang Y; Zhang J; Karnes RJ; He HH; Wang L; Wang C; Huang H
    Nat Commun; 2021 Sep; 12(1):5716. PubMed ID: 34588438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
    Nikhil K; Haymour HS; Kamra M; Shah K
    Br J Cancer; 2021 Mar; 124(5):995-1008. PubMed ID: 33311589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
    Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
    J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
    Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
    Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog.
    Cao J; Zhao M; Liu J; Zhang X; Pei Y; Wang J; Yang X; Shen B; Zhang J
    Theranostics; 2019; 9(3):811-828. PubMed ID: 30809310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers.
    Kim MS; Je EM; Oh JE; Yoo NJ; Lee SH
    APMIS; 2013 Jul; 121(7):626-33. PubMed ID: 23216165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SPOP suppresses testicular germ cell tumors progression through ubiquitination and degradation of DPPA2.
    Wang J; Zhuang H; Zhang H; Li Q; Cao X; Lin Z; Lin T; Chen X; Ni X; Yang J; Zhao Y; Shen L; Wang H; Zhu J; Ye M; Jin X
    Biochem Biophys Res Commun; 2021 Jun; 557():55-61. PubMed ID: 33862460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
    Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
    Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants.
    Ostertag MS; Hutwelker W; Plettenburg O; Sattler M; Popowicz GM
    J Mol Biol; 2019 May; 431(11):2213-2221. PubMed ID: 31026449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
    Tan Y; Ci Y; Dai X; Wu F; Guo J; Liu D; North BJ; Huo J; Zhang J
    Oncotarget; 2017 Jul; 8(29):47890-47901. PubMed ID: 28599312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
    Zhang L; Peng S; Dai X; Gan W; Nie X; Wei W; Hu G; Guo J
    Cancer Lett; 2017 Apr; 390():11-20. PubMed ID: 28089830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deficiency in SPOP-mediated ubiquitination and degradation of TIAM1 promotes gastric cancer progression.
    Liu F; Zhang T; Sun X; Liu Z; Xu W; Dai X; Zhang X
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167032. PubMed ID: 38246227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
    Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
    Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
    An J; Wang C; Deng Y; Yu L; Huang H
    Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
    Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
    Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
    García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
    Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
    Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
    EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1.
    Li C; Ao J; Fu J; Lee DF; Xu J; Lonard D; O'Malley BW
    Oncogene; 2011 Oct; 30(42):4350-64. PubMed ID: 21577200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.